Talking Medicines CLN Modifications

Summary by AI ^BETAClose X

Tern Plc has announced modifications to its convertible loan notes in Talking Medicines Limited, extending the maturity dates of approximately £0.3 million in CLNs to 21 November 2029. This move equalizes the terms and conditions across all tranches of Talking Medicines' outstanding CLNs, aligning them with those announced on 1 February 2024. The company's directors believe this strategic extension will enhance Tern's negotiating position for any future exit from its investment in Talking Medicines.

Disclaimer*

Tern PLC

25 November 2025

Tern Plc

("Tern" or the "Company")

Talking Medicines Convertible Loan Note Modifications

Tern Plc (AIM:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things ("IoT") technology businesses, announces that the maturity dates of the approximately £0.3 million of convertible loan notes ("CLNs") that the Company holds in Talking Medicines Limited ("Talking Medicines") have been extended, with all of Tern's CLNs in Talking Medicines being extended to 21 November 2029.

A proportion of the CLNs were due to mature on 30 November 2025 and the maturity dates of all of Talking Medicines' outstanding CLNs have now been extended, together with the terms and conditions of the various tranches of Talking Medicines CLNs being equalised, to reflect the CLN terms described in Tern's announcement of 1 February 2024. The Tern directors believe that this will place Tern in a more advantageous negotiating position with regard to any exit from Tern's holding in Talking Medicines.

Enquiries

Tern Plc

Jane McCracken (Interim Non-Executive Chair)

via IFC Advisory

Allenby Capital Limited

(Nominated Adviser and Broker)

Alex Brearley / Ashur Joseph (Corporate Finance)

Kelly Gardiner (Sales and Corporate Broking)

Tel: 0203 328 5656

IFC Advisory

(Financial PR and IR)

Tim Metcalfe

Graham Herring

Florence Staton

Tel: 0203 934 6630

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END